產(chǎn)品名稱 Elafibranor - GFT505
產(chǎn)品貨號(hào) Axon 2727 CAS [824932-88-9] MF C22H24O4SMW 384.49 Purity: 98% Soluble in 0.1N NaOH(aq) and DMSO Description The dual PPARα/δ agonist Elafibrinor (GFT505) (EC50 values of 45 nM and 175 nM for PPARα and PPARδ, respectively) is a liver-targeted insulin-sensitizer that is a drug candidate for the treatment of type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NAS). In animals, its protective effects are mediated by both PPAR-α-dependent and -independent mechanisms. KEYWORDS: Elafibranor | supplier | PPAR α/δ agonist | GFT505 | GFT 505 | GFT-505 | CAS [824932-88-9] | CAS [923978-27-2] | Metabolism | PPAR | Agonist | Receptors | Insulin | Diabetes | NAFLD | NAS | Steatohepatitis | Peroxisome Proliferator-activated Receptor
產(chǎn)品價(jià)格 現(xiàn)貨詢價(jià)，電話：010-67529703
產(chǎn)品規(guī)格
產(chǎn)品品牌 axonmedchem
產(chǎn)品概述
產(chǎn)品詳情

Elafibranor - GFT505

Based on 14 reference(s) in Google Scholar 8 10 14

Axon 2727

CAS [824932-88-9]

MF C22H24O4S
MW 384.49

  • Purity: 98%
  • Soluble in 0.1N NaOH(aq) and DMSO

Elafibranor

Description

The dual PPARα/δ agonist Elafibrinor (GFT505) (EC50 values of 45 nM and 175 nM for PPARα and PPARδ, respectively) is a liver-targeted insulin-sensitizer that is a drug candidate for the treatment of type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NAS). In animals, its protective effects are mediated by both PPAR-α-dependent and -independent mechanisms.

KEYWORDS: Elafibranor | supplier | PPAR α/δ agonist | GFT505 | GFT 505 | GFT-505 | CAS [824932-88-9] | CAS [923978-27-2] | Metabolism | PPAR | Agonist | Receptors | Insulin | Diabetes | NAFLD | NAS | Steatohepatitis | Peroxisome Proliferator-activated Receptor
產(chǎn)品資料